Newborn screening tests help detect diseases early in the first days of birth and provide timely treatment to reduce neonatal mortality, reduce the rate of mental and physical retardation, and reduce the burden on families and society.

G6PD deficiency is one of the most common genetic diseases. Statistics show that there are up to 400 million people in the world with this disease. So what is G6PD deficiency? Is it dangerous and how should it be detected and treated?

Newborn screening is a program of routine testing for newborns to detect early endocrine and metabolic disorders that affect the health and physical and mental development of children. Below are 3 types of diseases that are screened for newborns by blood tests.

Every baby born must ensure healthy physical and mental development. Therefore, from birth, newborns need to have screening tests to help detect diseases early and find timely treatment to reduce mortality rates and help children have a good start.

Performing postnatal screening 24-72 hours after birth by taking blood from the baby's heel helps doctors screen for certain genetic diseases and metabolic disorders in children, reducing the number of children with physical and mental retardation and many other diseases.

Newborn screening programs aim to detect metabolic disorders in children early, helping to prevent dangerous complications and giving children a normal, healthy life.

G6PD deficiency is very common, and children with G6PD deficiency can still develop normally if properly cared for. However, if not detected and treated promptly, children can suffer from serious sequelae, even cerebral palsy.

Congenital hypothyroidism is defined as a significant reduction or loss of thyroid function in a newborn baby, affecting the child's growth, physical and mental development. However, if detected and treated early, the child will have the opportunity to develop normally and healthily.

G6PD deficiency is a fairly common genetic enzyme disorder in humans. G6PD deficiency can lead to hemolysis, jaundice, yellow eyes and kidney failure. Newborn screening plays an extremely important role in early detection of the disease for active and effective treatment.

G6PD (Glucose-6-phosphate dehydrogenase) enzyme deficiency is a common disease in humans. Currently, there are about 400 million people in the world with the disease, South Asia is the region with a relatively high incidence rate of 3-5%.

Hemocyte lysis is a measure of the ability of red blood cells to rupture in different concentrations of hypotonic saline solution.